12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Esbriet regulatory update

InterMune said it reached an agreement with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) to price idiopathic pulmonary fibrosis (IPF) drug Esbriet pirfenidone at €26,999 ($32,806) per year, which is a 10% discount to the price at which InterMune launched the drug last September. The new price takes effect Sept. 15...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >